ABBV-119 / AbbVie - LARVOL DELTA

Study to Evaluate Adverse Events and Change in Disease Activity With Oral Capsules of Galicaftor/Navocaftor/ABBV-119 or Galicaftor/Navocaftor/ABBV-576 Combination Therapies in Adult Participants With Cystic Fibrosis (clinicaltrials.gov) - P2 | N=48 | Terminated | Sponsor: AbbVie | Active, not recruiting ➔ Terminated; Strategic considerations

Adverse events • Combination therapy • Trial termination • Cystic Fibrosis • Fibrosis • Genetic Disorders • Immunology • Pulmonary Disease • Respiratory Diseases • CFTR

Study to Evaluate Adverse Events and Change in Disease Activity With Oral Capsules of Galicaftor/Navocaftor/ABBV-119 or Galicaftor/Navocaftor/ABBV-576 Combination Therapies in Adult Participants With Cystic Fibrosis (clinicaltrials.gov) - P2 | N=48 | Active, not recruiting | Sponsor: AbbVie | Recruiting ➔ Active, not recruiting | N=90 ➔ 48 | Trial completion date: Nov 2023 ➔ Jun 2023 | Trial primary completion date: Oct 2023 ➔ Jun 2023

Adverse events • Combination therapy • Enrollment change • Enrollment closed • Trial completion date • Trial primary completion date • Cystic Fibrosis • Fibrosis • Genetic Disorders • Immunology • Pulmonary Disease • Respiratory Diseases • CFTR

Study to Evaluate Adverse Events and Change in Disease Activity With Oral Capsules of Galicaftor/Navocaftor/ABBV-119 or Galicaftor/Navocaftor/ABBV-576 Combination Therapies in Adult Participants With Cystic Fibrosis (clinicaltrials.gov) - P2 | N=90 | Recruiting | Sponsor: AbbVie | Active, not recruiting ➔ Recruiting

Adverse events • Combination therapy • Enrollment open • Cystic Fibrosis • Fibrosis • Genetic Disorders • Immunology • Pulmonary Disease • Respiratory Diseases • CFTR

Study to Evaluate Adverse Events and Change in Disease Activity With Oral Capsules of Galicaftor/Navocaftor/ABBV-119 or Galicaftor/Navocaftor/ABBV-576 Combination Therapies in Adult Participants With Cystic Fibrosis (clinicaltrials.gov) - P2 | N=90 | Active, not recruiting | Sponsor: AbbVie | Trial completion date: Oct 2022 ➔ Nov 2023 | Trial primary completion date: Sep 2022 ➔ Oct 2023

Adverse events • Combination therapy • Trial completion date • Trial primary completion date • Cystic Fibrosis • Fibrosis • Genetic Disorders • Immunology • Pulmonary Disease • Respiratory Diseases • CFTR

Study to Evaluate Adverse Events and Change in Disease Activity With Oral Capsules of Galicaftor/Navocaftor/ABBV-119 Combination Therapy in Adult Participants With Cystic Fibrosis (clinicaltrials.gov) - P2 | N=90 | Active, not recruiting | Sponsor: AbbVie | Recruiting ➔ Active, not recruiting

Adverse events • Combination therapy • Enrollment closed • Cystic Fibrosis • Fibrosis • Genetic Disorders • Immunology • Pulmonary Disease • Respiratory Diseases

Study to Evaluate Adverse Events and Change in Disease Activity With Oral Capsules of Galicaftor/Navocaftor/ABBV-119 Combination Therapy in Adult Participants With Cystic Fibrosis (clinicaltrials.gov) - P2; N=90; Recruiting; Sponsor: AbbVie; Trial primary completion date: Dec 2021 ➔ Sep 2022

Adverse events • Clinical • Combination therapy • Trial primary completion date • Cystic Fibrosis • Fibrosis • Genetic Disorders • Immunology • Pulmonary Disease • Respiratory Diseases

A Study of Galicaftor/Navocaftor/ABBV-119 Combination Therapy in Subjects with Cystic Fibrosis. (clinicaltrialsregister.eu) - P2; N=90; Ongoing; Sponsor: AbbVie Deutschland GmbH & Co. KG

Clinical • Combination therapy • New P2 trial • Cystic Fibrosis • Fibrosis • Genetic Disorders • Immunology • Pulmonary Disease • Respiratory Diseases

Study to Evaluate Adverse Events and Change in Disease Activity With Oral Capsules of Galicaftor/Navocaftor/ABBV-119 Combination Therapy in Adult Participants With Cystic Fibrosis (clinicaltrials.gov) - P2; N=90; Recruiting; Sponsor: AbbVie; Trial completion date: Apr 2022 ➔ Dec 2022

Adverse events • Clinical • Combination therapy • Trial completion date • Cystic Fibrosis • Fibrosis • Genetic Disorders • Immunology • Pulmonary Disease • Respiratory Diseases

Study to Evaluate Adverse Events and Change in Disease Activity With Oral Capsules of Galicaftor/Navocaftor/ABBV-119 Combination Therapy in Adult Participants With Cystic Fibrosis (clinicaltrials.gov) - P2; N=90; Recruiting; Sponsor: AbbVie; Not yet recruiting ➔ Recruiting

Adverse events • Clinical • Combination therapy • Enrollment open • Cystic Fibrosis • Fibrosis • Genetic Disorders • Immunology • Pulmonary Disease • Respiratory Diseases

Study to Evaluate Adverse Events and Change in Disease Activity With Oral Capsules of Galicaftor/Navocaftor/ABBV-119 Combination Therapy in Adult Participants With Cystic Fibrosis (clinicaltrials.gov) - P2; N=90; Not yet recruiting; Sponsor: AbbVie; N=50 ➔ 90; Trial completion date: Jan 2022 ➔ Apr 2022

Adverse events • Clinical • Combination therapy • Enrollment change • Trial completion date • Cystic Fibrosis • Fibrosis • Genetic Disorders • Immunology • Pulmonary Disease • Respiratory Diseases

Study to Evaluate Adverse Events and Change in Disease Activity With Oral Capsules of Galicaftor/Navocaftor/ABBV-119 Combination Therapy in Adult Participants With Cystic Fibrosis (clinicaltrials.gov) - P2; N=50; Not yet recruiting; Sponsor: AbbVie

Adverse events • Clinical • Combination therapy • New P2 trial • Cystic Fibrosis • Fibrosis • Genetic Disorders • Immunology • Pulmonary Disease • Respiratory Diseases